OptimizeRx Corporation (OPRX)
OPRX Stock Price Chart
Explore OptimizeRx Corporation interactive price chart. Choose custom timeframes to analyze OPRX price movements and trends.
OPRX Company Profile
Discover essential business fundamentals and corporate details for OptimizeRx Corporation (OPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Information Services
IPO Date
28 Nov 2007
Employees
128.00
Website
https://www.optimizerx.comCEO
Stephen L. Silvestro
Description
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
OPRX Financial Timeline
Browse a chronological timeline of OptimizeRx Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is $0.03.
Earnings released on 7 Aug 2025
EPS came in at $0.24 surpassing the estimated $0.03 by +700.00%, while revenue for the quarter reached $29.20M , beating expectations by +22.50%.
Earnings released on 12 May 2025
EPS came in at $0.08 surpassing the estimated -$0.11 by +172.73%, while revenue for the quarter reached $21.93M , beating expectations by +17.35%.
Earnings released on 12 Mar 2025
EPS came in at $0.30 surpassing the estimated $0.25 by +20.00%, while revenue for the quarter reached $32.32M , beating expectations by +72.09%.
Earnings released on 13 Nov 2024
EPS came in at $0.12 surpassing the estimated $0.06 by +100.00%, while revenue for the quarter reached $21.31M , missing expectations by -29.37%.
Earnings released on 8 Aug 2024
EPS came in at $0.02 surpassing the estimated -$0.07 by +128.57%, while revenue for the quarter reached $18.81M , missing expectations by -6.83%.
Earnings released on 16 Apr 2024
EPS came in at $0.26 surpassing the estimated -$0.13 by +300.00%, while revenue for the quarter reached $19.69M , beating expectations by +8.60%.
Earnings released on 28 Mar 2024
EPS came in at $0.26 falling short of the estimated $0.32 by -18.75%, while revenue for the quarter reached $28.37M , beating expectations by +7.17%.
Earnings released on 6 Nov 2023
EPS came in at $0.09 surpassing the estimated $0.03 by +260.00%, while revenue for the quarter reached $16.33M , beating expectations by +7.37%.
Earnings released on 14 Aug 2023
EPS came in at -$0.01 falling short of the estimated -$0.01 by -53.37%, while revenue for the quarter reached $13.82M , missing expectations by -6.70%.
Earnings released on 10 May 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $13.00M , beating expectations by +5.29%.
Earnings released on 8 Mar 2023
EPS came in at $0.25 surpassing the estimated $0.24 by +4.17%, while revenue for the quarter reached $19.65M , missing expectations by -9.72%.
Earnings released on 8 Nov 2022
EPS came in at $0.07 surpassing the estimated $0.04 by +90.68%, while revenue for the quarter reached $15.09M , beating expectations by +1.13%.
Earnings released on 9 Aug 2022
EPS came in at $0.04 falling short of the estimated $0.10 by -60.00%, while revenue for the quarter reached $13.98M , missing expectations by -18.08%.
Earnings released on 4 May 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -15.21%, while revenue for the quarter reached $13.73M , beating expectations by +1.37%.
Earnings released on 24 Feb 2022
EPS came in at $0.22 surpassing the estimated $0.18 by +22.22%, while revenue for the quarter reached $20.31M , beating expectations by +0.76%.
Earnings released on 9 Nov 2021
EPS came in at $0.09 falling short of the estimated $0.13 by -30.77%, while revenue for the quarter reached $16.12M , beating expectations by +7.43%.
Earnings released on 4 Aug 2021
EPS came in at $0.10 surpassing the estimated $0.07 by +42.86%, while revenue for the quarter reached $13.63M , beating expectations by +9.44%.
Earnings released on 6 May 2021
EPS came in at $0.03 surpassing the estimated $0.01 by +275.00%, while revenue for the quarter reached $11.23M , beating expectations by 0.00%.
Earnings released on 24 Feb 2021
EPS came in at $0.16 surpassing the estimated $0.15 by +6.67%, while revenue for the quarter reached $16.43M , meeting expectations.
Earnings released on 9 Nov 2020
EPS came in at $0.07 surpassing the estimated $0.04 by +75.00%, while revenue for the quarter reached $10.52M , beating expectations by +7.74%.
OPRX Stock Performance
Access detailed OPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.